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Abstract
Background: Haemodialysis (HD) is one of the life-saving options for patients with end stage renal disease but
demand for this treatment exceeds capacity in publicly funded hospitals. One novel approach to addressing this
problem is through a shared-care model whereby government hospitals partner with qualified private HD service
providers to increase the accessibility of HD for needy patients. The aim of this study is to evaluate and enhance the
quality of care (QOC) provided in such a shared-care programme in Hong Kong, the Haemodialysis Public-Private
Partnership Programme (HD-PPP).
Methods/Design: This is a longitudinal study based on Action Learning and Audit Spiral methodologies to measure
the achievement of pre-set target standards for the HD-PPP programme over three evaluation cycles. The QOC
evaluation framework is comprised of structure, process and outcome criteria with target standards in each domain
developed from review of the evidence and in close collaboration with the HD-PPP working group. During each
evaluation cycle, coordinators of each study site complete a questionnaire to determine adherence with structural
criteria of care. Process and clinical outcomes, such as adverse events and dialysis adequacy, are extracted from the
patient records of consenting study participants while face-to-face interviews are conducted to ascertain patient-
reported outcomes such as self-efficacy and health-related quality of life.
Discussion: The study relies on the successful implementation of partnership-based action research to develop an
evidence-based and pragmatic framework for evaluation of quality of care in an iterative fashion, and to use it to
identify possible areas of quality enhancements in a shared-care programme for HD patients. The approach we take in
this study emphasizes partnership and engagement with the clinical and administrative programme team, a robust but
flexible evaluation framework, direct observation and the potential to realize positive change. The experience will be
useful to inform the process of coordinating research studies involving multiple stakeholders and results will help to
guide service planning and policy decision making.
Trial registration: US Clinical Trial Registry NCT02307903
Keywords: Haemodialysis, End stage renal disease, Community centre, Hospital, Quality of care, Action research, Audit,
Shared care
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Background
End-stage renal disease (ESRD) is a state in which the
kidneys do not function sufficiently to sustain life. Pa-
tients with ESRD require renal transplantation, haemodi-
alysis or peritoneal dialysis as a form of renal
replacement therapy (RRT) in order to survive [1].
Worldwide prevalence of ESRD is anticipated to rise in
tandem with the increasing prevalence of diabetes melli-
tus and hypertension globally which will drive future de-
mand for RRT [2] and underlines the necessity of
developing approaches to meet this need [3]. Haemodi-
alysis (HD) is generally the preferred mode of therapy
when renal transplantation is not possible, but it is ex-
pensive and resource-intensive [4]. In Hong Kong the
Hospital Authority (HA), which is the government body
which oversees public hospitals, has thereby adopted a
“peritoneal dialysis (PD) first” policy for ESRD patients
eligible for RRT [5]. HD is currently reserved for ESRD
patients who have failed or have contraindications for
PD.
HD has traditionally been performed in hospital-based
settings with increasing demand necessitating expansion
to satellite clinics (either hospital-linked public clinics or
privately funded independent clinics) or home-based
HD. A review of satellite HD clinics in the United King-
dom found no significant differences in clinical pro-
cesses of care or clinical outcomes compared with
hospital clinics [6]. A further systematic review that
found that both home and satellite unit HD were some-
what better that hospital HD in most measures of effect-
iveness including quality of life and survival [7]. This,
coupled with better accessibility and higher patient ac-
ceptability, suggests that satellite community clinics have
the potential to be effective alternatives to traditional in-
hospital units for HD patients. On this background, a
new service provision model was introduced in Hong
Kong by the HA in 2010 to expand the capacity to ac-
commodate patients with ESRD needing HD. The
Haemodialysis Public-Private Partnership (HD-PPP)
programme [8] involves the sharing of care of HD pa-
tients between public hospital-based renal units and
qualified community-based HD clinics. This programme
allows participants to receive HD treatment in the com-
munity, while continuing to receive usual follow up care
at the partner public hospital.
The target population for the HD-PPP programme in-
clude existing HA patients who fulfill the designated
clinical criteria and are currently receiving HD in HA
hospitals, new ESRD patients with contraindications for
PD or patients who are currently on PD but are at risk
of treatment failure. Eligible patients who choose to en-
roll in the programme will receive HD treatment in their
selected community HD centre run by a private or char-
itable organization, and will pay no additional fees. The
frequency of dialysis and other medical decisions would
be overseen by the HA nephrologist looking after that
particular patient. HD-PPP participants are followed up
regularly at the renal specialist outpatient clinic (SOPC)
to monitor their HD adequacy, renal function and other
relevant clinical parameters.
As part of the development of a new health care ser-
vice programme, it is important to include an evaluation
component, best undertaken by an independent third
party working in close collaboration with the
programme planners, providers and administrators, to
examine whether the programme delivers the care that
it is intended to deliver, to the desired standard. The ef-
fectiveness of the programme in benefitting the health of
service recipients and the sustainability of the
programme can also be determined over a longer period
of time. Such findings will provide valuable evidence to
help those providing front-line care as well as those de-
veloping and coordinating the programme to improve
the quality of patient care, and to support the continued
funding and expansion of the programme.
Aim of study
The aim of this study is to evaluate the quality of care
and effectiveness of the HD-PPP programme for HD pa-
tients under the shared care of publically-funded hos-
pital renal units and affiliated community HD centres in
Hong Kong. An evidence-based, structured and compre-
hensive evaluation framework will be developed and
used to identify areas for quality enhancement.
The objectives of the study are to:
1) Review and identify the structure, process and
outcome indicators of QOC;
2) Identify the criterion and set the target standard for
each indicator;
3) Compare the observed standards against the target
standards;
4) Identify any on-site problems related to implementa-
tion of the programme
5) Provide feedback on the QOC of the programme;
6) Identify possible areas for improvement;
7) Give recommendations for enhancement of service
delivery.
Hypotheses
The following hypotheses will be tested:
1) The criteria on structure and process should be
achieved by all participating HA renal units and
community HD centres;
2) The dialysis for patients should be adequately
maintained (Kt/V ≥ 1.2 for patients receiving 3 HD
sessions per week or ≥ 1.8 for those receiving 2 HD
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sessions per week) after 12, 24, 36 and 48 months in
the programme;
3) Patients in the programme should report no worse
outcomes as patients managed by usual care in the
HA (control);
Methods/Design
The Action Learning [9] and Audit Spiral methodologies
[10] will be used to carry out a systematic analysis of the
QOC and to identify areas for enhancement in the HD-
PPP programme. Donabedian’s taxonomy of QOC on
structure, process and outcomes will be used as the tem-
plate for the evaluation framework [11]. Three audit-
spiral evaluation cycles will be carried out with feedback
of results and a quality enhancement action plan to be
implemented which aims at a higher level of QOC for
each subsequent evaluation cycle.
Investigators will work together with the HD-PPP
programme team to:
1) Review and identify the structure, process and
outcome indicators;
2) Define the criterion and set the target standard for
each indicator;
3) Identify any on-site problems of implementation of
the programme;
4) Provide interim feedback on QOC of the
programme;
5) Identify possible actions for improvements;
6) Compare the observed standards against the pre-set
target standards;
7) Make recommendations about the programme.
A QOC evaluation framework will be developed using
an iterative approach, relying on reconciliation between
the investigators and the programme providers to come
to a consensus balancing evidence with practical consid-
erations (Fig. 1). This framework lists the indicators of
the structure (staff, facilities, organization, and manage-
ment), process (what, when and how care is delivered),
and outcomes (clinical and patient reported outcomes)
with the required criteria and standard of care to be
achieved (Additional file 1 – evaluation framework).
Subjects
All patients participating in the HD-PPP programme be-
tween 1 March 2010 and 30 June 2014 will be included
in the evaluation on process of care. All HD-PPP partici-
pants and an equal number of non-HD-PPP participants
(eligible for HD-PPP but not participating) matched by
age and gender will be included in the evaluation on the
outcomes of care. The non-HD-PPP subjects will be se-
lected from the HA patient database by the HA Statistics
and Workforce Planning Department. Subjects will be
recruited via a letter from the HA or on-site by HKU re-
search assistants upon enrolment in the HD-PPP
programme.
Data collection
Evaluation on structure and process
The programme coordinator of each participating HA
renal unit and community HD service provider will be
asked to complete a written structure of care question-
naire. For some questions respondents are also re-
quested to submit evidence to support their response.
Incomplete or equivocal responses are clarified by tele-
phone and further confirmation and cross-validation is
made during scheduled site-visits. Anonymized data will
be retrieved from the computerized medical record sys-
tem (CMS) by the HA statistics team to determine the
process of care indicators including dropout rate, attend-
ance at hospitals or community HD centres, compliance
with follow up monitoring as per protocol etc.
Evaluation on outcomes of care
Anonymized data on clinical parameters at baseline, 12,
24, 36, 48 and 60 months after enrollment will be re-
trieved from the CMS by the HA statistics team.
For patient-reported outcomes, HD-PPP subjects and
non-HD-PPP subjects will be invited in person at the com-
munity centre/renal unit to complete a telephone/face-to-
face survey on health-related quality of life at enrolment
into the HD-PPP (or equivalent time for non-HD-PPP),
Step 1
• Drafting of generic quality of care indicator framework: Research team 
Step 2
• Defining of indicators and criteria: Programme providers
Step 3
• Refining of programme specific indicators, criteria & standards: Research 
team
Step 4
• Setting of indicators, criteria & standards: Programme providers
Step 5
• Reconciling indicators, criteria, standards and operational definitions: 
Research team and programme providers
Step 6
• Reviewing and finalizing an evidence-based, practical framework: 
Programme providers
Fig. 1 Development of the evaluation framework: an iterative and
collaborative process
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and then again at 12, 24, 36, 48 and 60 months. The follow
up surveys will also include questions assessing patient en-
ablement and global rating of change in health condition.
The trained research assistant administering the patient-
reported outcomes questionnaire survey will also obtain
written informed consent from each patient prior to com-
mencing the survey.
Three evaluation and feedback cycles
Three evaluation (audit) cycles will be conducted with
each having a specific focus. The first evaluation cycle
tries to identify discrepancies between intended targets
and actual practice in which may require changes in the
structure and process of care. The second evaluation
cycle is to determine the standards that are achievable
after the HD-PPP programme has been established. The
third evaluation cycle aims to assess the sustainability of
the standards of care, and to document the impact of
the HD-PPP programme. Each evaluation cycle involves
an initial planning meeting to agree on the criteria for
evaluation and the target standards, site visits by the re-
search team to observe the programme in action, to
cross-validate structural and process elements and to
clarify areas of confusion, the collection and analysis of
preliminary data, and a feedback meeting with
programme coordinators and administrators to discuss
findings, identify areas for quality enhancement and re-
vise the evaluation framework as necessary. The evi-
dence generated by the study serves as an impetus for
changes to be made to the programme.
Outcome measures
Primary
1) The proportion of centres that have satisfied each
pre-set structure criterion
2) The proportion of patients who have complied with
the process of care
3) The proportion of patients who have adequate HD
measured by the Kt/V
Secondary
1) Clinical outcomes include dialysis adequacy and
blood haemoglobin.
2) Patient reported outcomes (PRO) are measured by
the change in Short Form-12 version 2 (SF-12v2)
scores, the Patient Enablement Instrument (PEI) and
Global Rating Scale (GRS) scores at baseline and
after 12 months.
Study instruments
There are four study instruments are used in this study,
one to evaluate the structure of care and three to
evaluate the PRO (Kidney Disease Quality of Life
(KDQOL-36), the PEI and the GRS). Evaluation of the
process and outcomes of care do not involve the use of
study instruments as the necessary data are retrieved
from the HA computerized medical record system by
the Statistics and Workforce Planning Department.
Structure of care questionnaire [Additional file 2- SOC
questionnaire]
Structure of care questionnaires are sent to the doc-
tor and nurse in-charge of the HD-PPP programme
at each study site for completion. The questionnaire
seeks to characterize the attributes of the setting in
which the health care service is delivered, including
the human resources and training (staff ); the hard-
ware needed (space, facilities, and data collection);
and the organization and management of the
programme.
Kidney Disease Quality of Life (KDQOL-36)
KDQOL-36 survey is a kidney disease specific measure
of health related quality of life [12]. It comprises generic
and disease-specific cores. The generic core is the Short
Form-12 Health Survey (SF-12). The SF-12 is a generic
HRQOL measure, which can be summarized into phys-
ical and mental component summary (PCS and MCS)
scores. The SF-12 has been validated for use in Hong
Kong [13]. The disease-specific core has 3 subscales (4
items for burden of kidney disease; 12 items for symp-
tom bother and problems and 8 items for effects of kid-
ney disease). The domain scores are calculated by
summation of the relevant item scores and transform-
ation into a range from 0 to 100, with higher scores indi-
cating better HRQOL.
The Patient Enablement Instrument (PEI)
PEI will be used to measure patient’s enablement in
coping with the illness and life [14]. It has 6 items
and each rated on a 3-point scale (0 = the same or
less; 1 = slightly improved/increased; 2 = greatly im-
proved/increased). The summation of the item scores
gives the PEI score with a higher score indicating bet-
ter enablement. The PEI has been translated into
Chinese and shown to be valid and reliable in the
general Chinese population [15].
The Global Rating Scale (GRS)
GRS, adapted from studies [16, 17], will be used to as-
sess the subject’s global perception of any change in
their overall health condition on a 7-point scale (−3 =
much worse to 3 =much improved, with 0 = no change)
over the past 12 months.
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Data analysis
1) Descriptive statistics on standard of care will be
calculated including the percentage of centres
meeting each structure criterion, percentage of
subjects enrolled, dropped out, receiving criterion
process including HD, and percentage of subjects
achieving each outcome criterion.
2) The difference in clinical and PRO of patients who
take part in the HD-PPP programme at baseline, 12,
24, 36 and 48 months will be compared by paired
sample t-tests.
3) Independent sample t-test or chi-square test as ap-
propriate will be used to compare the clinical out-
comes between HD-PPP participants and control
patients.
4) Independent sample t-test or chi square test as ap-
propriate will be used to compare the clinical out-
comes between results achieved in different
evaluation cycles.
Ethics, consent and permissions
This study has received ethics approval from the Institu-
tional Review Board of the University of Hong Kong
Hospital Authority Hong Kong West (UW 10–366),
Hong Kong East (HKEC-2010-096), Kowloon East and
Kowloon Central (KC/KE-10-0208/ER-3), Kowloon West
(KW/EX/10-150 (34–17), New Territories East (CRE-
2011.051) and New Territories West clusters (NTWC/
CREC911-11). Written informed consent was received
from each patient prior to commencing the survey.
Trial status
The first two evaluation cycles have been completed
resulting in a final QOC evaluation framework devel-
oped for use in the third evaluation cycle based on new
and revised indicators and target standards. The third
evaluation cycle began in April 2012 and data collection
is ongoing.
Discussion
The HD-PPP is a novel programme which is increasing
the availability of publically funded HD for needy ESRD
patients. With 725 patients receiving HD in publically
funded hospitals as of December 31, 2011 [18] and a cu-
mulative total of 120 patients ever being enrolled in the
HD-PPP as of March 31, 2012, the HD-PPP has already
expanded the capacity for HD by roughly 17 %. There
remains a waitlist for available vacancies supporting the
popularity of this programme. This evaluation study will
provide objective evidence to inform decisions about its
continuation and further expansion and to encourage
ongoing improvements.
Two similar programme evaluation studies on the Risk
Assessment and Management Programme for diabetic
[19] and for hypertensive patients [20] in primary care
are currently underway in Hong Kong. These authors
highlight a variety of issues encountered when doing ac-
tion research including the importance of stakeholder
collaboration and communication, regular feedback and
planning meetings, data monitoring and protocol adher-
ence, which are also applicable to our evaluation of the
HD-PPP programme. Some of the specific observations,
lessons learned and challenges encountered as we carry
out the HD-PPP evaluation study are discussed below.
Partnership approach
The HD-PPP programme itself emphasizes the centrality
of partnership between colleagues and organizations in
the public and private sectors in order to successfully
implement the programme. The study to evaluate the
quality of care provided by the HD-PPP is also reliant
on partnership to achieve its goals. Our academic re-
search team is comprised of primary care clinician-
researchers and statisticians whose expertise is in evalu-
ation, and the study requires close partnership with
those with complementary expertise in the content, lo-
gistics, information systems and patient care aspects of
HD and the programme. This includes the programme
administrative team from the HA head office, renal spe-
cialist colleagues in medicine and nursing from the HD-
PPP workgroup, frontline clinical staff and programme
coordinators at each of the 15 hospital renal unit and 7
community HD centre study sites, and members of the
HA information technology and statistical teams. The
diversity of the group brings multiple valid perspectives
– and vested interests – to the evaluation study. Re-
searchers seek to assure a rigorous approach to the
evaluation based on solid theoretical frameworks,
programme administrators focus on outcomes and re-
sources while frontline health care providers may have
concerns about workload and practical issues. As such,
it is vital to build trust and mutual understanding in
order to make this partnership and evaluation study ef-
fective. This is achieved by (i) emphasizing our shared
goal to enhance the quality of the programme, rather
than to blame or to find fault, which sets the tone of the
project as one that is cooperative rather than conten-
tious, (ii) having regular planning meetings in which
candid discussion to negotiate a balance between the
ideal and the practical may take place without com-
promising the rigour of the study, (iii) having timely and
regular feedback meetings to share interim findings and
to discuss actions to address shortfalls or difficulties, (iv)
keeping and circulating accurate meeting records en-
dorsed by attendees to ensure that discussion points,
conclusions and action plans are clear, and (v) assuring
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participating study sites that information collected from
structure of care questionnaires and site visits will be
anonymized and presented collectively to encourage
respondents to be honest and candid, which can also
improve the validity of the results and permit all sites to
learn from variations in practice.
Evaluation framework development
The evaluation framework forms the crux of the evalu-
ation study and its development is necessarily a detailed-
oriented and collaborative but time-intensive effort. The
aspects of the programme to be evaluated are derived
from a review of the relevant international and local
literature and information about the programme pro-
vided by stakeholders. The content is translated into an
evaluation framework with target standards agreed upon
by the group. The chosen target standard for each criter-
ion should be set so that it encourages quality improve-
ment but must balance what is ideal and desirable with
what is realistic and achievable in the given context. The
language used to articulate the criteria in the evaluation
framework also matters, as it needs to accurately and
unambiguously reflect the intention of the criterion.
What may seem clear to the research group may be
interpreted differently by a questionnaire respondent.
For example, we had a criterion in an initial version of
the structure of care questionnaire stating that “there
must be a record of enrolled patients kept in the elec-
tronic patient record” which inadvertently addresses two
issues: whether there is a record of enrolled patients,
and whether the electronic patient record is used to
keep the enrolment record. A respondent may respond
“no” if either part is not fulfilled which will make data
interpretation difficult without further clarification.
Though the structural template of the evaluation frame-
work remains fixed, the specific content evolves because
of the iterative nature of the evaluation process and the
evolution of the HD-PPP programme itself over time.
Value of direct observation
Site visits to all the study sites help to assure and cross-
validate quality of structure and process of care, to
observe the implementation of quality enhancement
strategies, to note variations in practice, and to docu-
ment good practices or improvements in practice to
share across the programme. Direct observation of the
programme in action across all the study sites enables us
to see the written programme protocol operationalized.
It is an opportunity to see the facilities and to gain an
understanding of how electronic platforms are used and
accessed, to get feedback from the front line healthcare
staff about their true experience and to follow a patient
journey from beginning to end. All of this contributes to
our understanding of the programme including its
constraints and possibilities, and strengthens the rela-
tionship with the colleagues at the study sites.
Potential to realize change
Even before results are compiled, the process of evalu-
ation is a valuable exercise. It draws attention to prac-
tices that are taken for granted and motivates change.
For example, Kt/V is widely recognized as a good indica-
tor of dialysis adequacy and is used in clinical practice
for patient management. It is also the primary clinical
outcome indicator for this evaluation study. In the
process of collecting data, we noted that it was not easy
to collect Kt/V data because it is recorded in the open-
text clinical consultation notes section of the electronic
patient record or manually in paper record summaries,
which cannot be extracted automatically. For patients in
the HD-PPP a separate module of the electronic patient
record has a designated Kt/V field but completing it is
optional. To optimize the usefulness of Kt/V data, these
need to be recorded in such a way that is systematic and
easily retrievable by those involved in the patient’s care.
This was discussed during a feedback meeting with the
HD-PPP workgroup, leading to a pragmatic solution
ensuring that Kt/V of every dialysis patient would be
recorded annually in the electronic renal patient registry.
Conclusion
As the demand for HD grows, programmes such as the
HD-PPP will help to shorten the waiting time for HD
for ESRD patients and relieve the burden on public
hospitals. A formal, independent and rigorous evaluation
is necessary to assure that the programme is achieving
its purpose and having a positive impact on patient care.
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